Technical briefs on lateral flow immunoassays, fluorescent detection, digital readers and laboratory system integration.
Laboratory information system integration matters for a point-of-care reader because a result that stays on the device never reaches the laboratory record, the patient chart or the quality system. Connecting…
Rapid cancer diagnostic technologies are assay formats and instruments designed to measure a cancer-associated biomarker near the point of sampling, without sending the specimen to a central laboratory. The main…
Fluorescent and gold nanoparticle lateral flow assays share the same strip and the same antibody chemistry; they differ in the label attached to the detection antibody and in how the…
A lateral flow assay works by letting a liquid sample wick along a strip of porous membrane, carrying labeled antibodies past a line of immobilized capture reagent. If the target…
Researchers applied MIGHT to liquid biopsy data, focusing on ccfDNA fragmentation patterns (e.g., fragment lengths, positions, and end motifs) to determine which features reliably indicate cancer: Challenge: False Positives Linked…
OncoFirm Diagnostics | https://oncofirmdiagnostics.com 1. Executive Summary The intersection of artificial intelligence (AI) and biomarker science is revolutionizing early cancer detection. By leveraging AI algorithms to analyze complex biological signals, OncoFirm…
Fluorescent LFA vs Traditional Testing
AI-Driven Biomarkers: Transforming Cancer Detection Through Multimodal Intelligence Introduction The integration of artificial intelligence (AI) into healthcare has revolutionized biomedical research, diagnostics, and patient care. One of the most promising…
RNA Polymerase II Levels in Histone Genes: A Predictive Biomarker for Tumor Aggressiveness and Recurrence Introduction Histone genes play a fundamental role in DNA packaging and chromatin structure, and their…
Our primary corporate website is now OncoFirm.com.
Visit our main website for the latest information about our cancer diagnostic technologies, research programs, intellectual property, corporate developments, partnerships and investor opportunities.
Continue to OncoFirm.com